A Supported Treatment programme designed at launch for the world as it exists at launch will not survive the world as it becomes. Lifecycle programme design builds the architecture that compounds — from pre-launch evidence integration through growth, patent defence, and the post-generic period where the programme becomes the primary competitive differentiator.
→ Design the full programme architecture across the product lifecycle: pre-launch, launch, growth and optimisation, patent defence, and post-patent retention phases
→ Define the pre-launch programme brief — how patient journey research, HCP co-design, and support module integration become part of the clinical trial protocol rather than a post-approval afterthought
→ Build the onboarding and first-six-weeks intervention design: the highest-leverage window in any treatment journey, where structured human support and friction removal produce the largest persistence gains
→ Design the omnichannel programme architecture — web, app, HCP workflow, pharmacy, nurse, and community components — and the logic that determines which channel owns which moment
→ Define the shared asset library model: how programme components are built once and deployed across brands and markets, accumulating institutional learning rather than being rebuilt from scratch at each launch
→ Build the affiliate localisation framework — how global programme design enables local execution without local reinvention, and where local adaptation is genuinely required versus where it undermines consistency
→ Design the patient journey measurement architecture: milestone-based persistence tracking, early drop-off detection, and real-world outcome capture built into the programme from inception
→ Develop the patent defence programme layer: the Phase 4 evidence strategy, the patent and trademark filing brief for the combined product-plus-programme model, and the HCP trust infrastructure that generics cannot replicate
→ Design the post-patent programme strategy: how Supported Treatment becomes the primary brand differentiator when the molecule is no longer protected, and what evidence base is needed to sustain it
→ Advise on technology partner selection and build-versus-buy decisions: what to own, what to platform, and what criteria determine whether a digital tool strengthens or fragments the programme experience